Analysts

Analysts watch Salesforce (CRM) and Snowflake (SNOW) ahead of earnings reports

05/26/2026, 11:33 AM investing review Analysts: analysts, Freedom Capital Markets software Snowflake Salesforce

Jay Woods, chief market strategist at Freedom Capital Markets, is closely monitoring Salesforce and Snowflake as they prepare to report earnings, highlighting potential bullish reversals for both stocks despite their year-to-date declines.

Analysts Evercore ISI and Bernstein recommend buying Ferrari (RACE) shares despite 6% decline following electric vehicle launch

05/26/2026, 10:36 AM investing recommendation Analysts: analysts, Bernstein, Evercore ISI auto Ferrari

Ferrari's shares dropped 6% following the launch of its first all-electric vehicle, the Luce, which received negative feedback online. Analysts suggest that despite initial reactions, the vehicle could attract new customers and ultimately boost sales.

Analysts expect Zscaler (ZS) to perform well ahead of earnings report amid strong revenue growth and AI security potential

05/26/2026, 10:36 AM investing forecast Analysts: analysts ai software Zscaler

Zscaler is positioned for potential growth as it approaches earnings, with strong revenue growth and a clean balance sheet, despite some market concerns.

Analysts Bank of America raised Apple (AAPL) target price to $380, citing AI shift as a growth opportunity

05/26/2026, 10:36 AM investing rating_growth Analysts: analysts, Bank of America ai software Apple

Bank of America has upgraded its outlook on Apple, raising its price target to $380, citing the company's potential to leverage artificial intelligence advancements through its user data control.

Analysts Roth highlight bullish sentiment in space stocks following SpaceX’s IPO filing

05/26/2026, 10:36 AM investing review Analysts: analysts, Cantor Fitzgerald space finance VanEck Intuitive Machines Rocket Lab

The recent filing for SpaceX's IPO has ignited a significant rally in space stocks, attracting retail investors eager to capitalize on what could be the largest IPO in history. This surge is benefiting both direct competitors and suppliers within the space sector, indicating a broader bullish sentiment in the market.

Analysts recommend buying Marvell Technology (MRVL) shares on pullback strategy ahead of earnings

05/26/2026, 10:36 AM investing recommendation Analysts: analysts semiconductors Marvell Technology

Marvell Technology (MRVL) has seen significant stock price increases due to strong demand in AI infrastructure and custom silicon, but caution is advised ahead of its upcoming earnings report due to high valuations and market expectations.

Analysts UBS raised Micron Technology (MU) target price to $1,625 on strong AI demand for memory chips

05/26/2026, 08:34 AM economy rating_growth Analysts: analysts, UBS ai semiconductors Micron Technology

Micron's stock surged 18%, pushing its market value past $1 trillion for the first time, fueled by strong demand for memory chips driven by artificial intelligence applications. UBS's significant price target increase reflects optimism about Micron's growth potential in the evolving tech landscape.

Analysts Ritholtz Wealth Management highlight CSX Corp. (CSX) as a top stock in the transport sector amid market volatility

05/26/2026, 08:34 AM investing review Analysts: analysts, Ritholtz industrials CSX Corporation

The transportation sector has shown strong performance despite recent volatility, with key players like CSX and Union Pacific poised for growth amid ongoing mergers and operational improvements. Investors should pay attention to these developments as they could significantly impact stock valuations in the sector.

Analysts recommend a bull call spread strategy for Northrop Grumman (NOC) amid recent price decline

05/26/2026, 08:34 AM investing recommendation Analysts: analysts defense Northrop Grumman

Northrop Grumman's stock has dropped 30% in less than two months, but technical indicators suggest a potential turnaround, making it a point of interest for investors looking for entry opportunities.

Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment

05/26/2026, 07:32 AM investing rating_growth Analysts: analysts, Goldman Sachs biotech

Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.